Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: A pooled analysis of randomized trials

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 8, 2012, Pages 1036-1041

  Bryant, Kristina A ^a   McVernon, Jodie ^b   Marchant, Colin D ^c   Nolan, Terry ^b   Marshall, Gary S ^a   Richmond, Peter ^d   Marshall, Helen ^e,f   Nissen, Michael ^g   Lambert, Stephen B ^g   Aris, Emmanuel ^h   Mesaros, Narcisa ^h   Miller, Jacqueline M ⁱ  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

ⁱ GLAXOSMITHKLINE   (United States)

Author keywords

Haemophilus influenzae type b; MMR; Neisseria meningitidis serogroups C and Y; Toddlers; Vaccination; Varicella

Indexed keywords

CHICKENPOX VACCINE; HAEMOPHILUS INFLUENZAE TYPE B NEISSERIA MENINGITIDIS SEROGROUP C Y TETANUS TOXOID CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEASLES MUMPS RUBELLA VACCINE; PEDVAHIB; UNCLASSIFIED DRUG; VACCINE;

AGE; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL DESIGN; FEBRILE CONVULSION; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; OUTCOME ASSESSMENT; PAROTID GLAND DISEASE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SALIVARY GLAND DISEASE; SCHOOL CHILD; SEROCONVERSION; VACCINATION;

CHICKENPOX VACCINE; FEMALE; HAEMOPHILUS VACCINES; HUMANS; INFANT; MALE; MEASLES-MUMPS-RUBELLA VACCINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETANUS TOXOID; VACCINES, CONJUGATE;

EID: 84866118807     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.20357     Document Type: Article

References (10)

1. Nolan T, Lambert S, Roberton D, Marshall H, Richmond P, Streeton C, et al. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroupsC and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. Vaccine 2007; 25:8487-99; PMID:17996996; http://dx.doi.org/10.1016/j.vaccine.2007.10.013.
2. Habermehl P, Leroux-Roels G, Sänger R, Mächler G, Boutriau D. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic Do not when administered according to the 2-4 months schedule with a fourth dose at 12-18 months of age. Hum Vaccin 2010; 6:640-51; PMID:20697200; http://dx.doi.org/10.4161/hv.6.8.12154.
3. Marchant CD, Miller JM, Marshall GS, Blatter M, Aris E, Friedland LR, et al.; HibMenCY-TT 005 Study Group. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2010; 29:48-52; PMID:20035207; http://dx.doi.org/10.1097/INF.0b013e3181c3ce88.
4. Nolan T, Richmond P, Marshall H, McVernon J, Alexander K, Mesaros N, et al. Immunogenicity and safety of an investigational combined Haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 2011; 30:190-6; PMID:20948453; http://dx.doi.org/10.1097/INF.0b013e3181fcb2bf.
5. Bryant KA, Marshall GS, Marchant CD, Pavia-Ruiz N, Nolan T, Rinderknecht S, et al. Immunogenicity and safety of H. influenzae type b-N. meningitidis C/Y conjugate vaccine in infants. Pediatrics 2011; 127:1375-85; PMID:21624883; http://dx.doi.org/10.1542/peds.2009-992.
6. Marshall GS, Marchant CD, Blatter M, Aris E, Boutriau D, Poolman JT, et al. Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age.Pediatr Infect Dis J 2010; 29:469-71; PMID:20072077; http://dx.doi.org/10.1097/INF. 0b013e3181cdd379.
7. Advisory Committee on Immunization Practices. 2011 Child & Adolescent Immunization Schedules.http://www.cdc.gov/vaccines/recs/schedules/child- schedule.htm#printable. Accessed July 03, 2011.
8. ActHIB [package insert]. Swiftwater, PA: Sanofi Pasteur Inc. 2009.
9. Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, et al.; Consistency Lot Study Group for ProQuad. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatr Infect Dis J 2006; 25:615-22; PMID:16804432; http://dx.doi.org/10.1097/ 01.inf.0000220209.35074.0b.
10. Wellington K, Goa KL. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella. Drugs 2003; 63:2107-26; PMID:12962524; http://dx.doi.org/10.2165/00003495-200363190- 00012.